GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Biogen Idec Inc (BIIB) [hlAlert]

Rating:
Buy BIIB
up 545.10 %

Biogen Idec Inc (BIIB) rated Buy with price target $60 by Stanford Research

Posted on: Thursday,  Sep 11, 2008  8:25 AM ET by Stanford Research

Stanford Research rated Buy Biogen Idec Inc (NASDAQ: BIIB) on 09/11/2008, when the stock price was $47.20. Since
then, Biogen Idec Inc has gained 545.11% as of 01/07/2016's recent price of $304.49.
If you would have followed this Stanford Research's recommendation on BIIB, you would have gained 545.1% of your investment in 2674 days.

Biogen Idec Inc. is engaged in the development, manufacturing, and commercialization of therapies. The Company?s products address diseases such as multiple sclerosis, non-Hodgkin?s lymphoma (NHL), rheumatoid arthritis (RA), crohn?s disease (CD) and psoriasis. The Company has four products: AVONEX (interferon beta-1a), RITUXAN (rituximab), TYSABRI (natalizumab) and FUMADERM (dimethylfumarate and monoethylfumarate salts). AVONEX is used in the treatment of relapsing forms of multiple sclerosis (MS). RITUXAN is one of the selling oncology therapeutics. In the United States, RITUXAN is approved for NHL. TYSABRI is approved for the treatment of relapsing forms of MS. FUMADERM acts as an immunomudulator. The Company also has product candidates, such as BG-12, which is a oral fumarate; ANTI-CD80 monoclonal antibody (MAb)(galiximab); ANTI-CD23 MAb (lumiliximab); Humanized Anti-CD20 MAb (ocrelizumab), Lixivaptan, an oral compound for the potential treatment of hyponatremia, and ADENTRI.

Stanford Research encompasses both institutional equity research and Washington-focused policy research, offering a perspective on individual companies, sector-specific topics and national policy. The importance Stanford Group Company places on research comes from years of experience in a constantly changing world. We know that as markets develop and new sectors grow, it is imperative that our clients have the most accurate information available to ensure financial success. Stanford Group Company clients will always have our commitment to conduct informative and enlightening research. As a part of our commitment to our clients, we provide objective, well-developed research. Our skilled analysts use their talent to provide invaluable research that can help in making important decisions. Thanks to a wide range of resources obtained through technology, experience and reputation, our research analysts develop reports on the most current firms and sectors. Our equity analysts offer insight and opinions on companies in the consumer/retail, media, energy, financial institutions, health care, technology and water/environment sectors.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
9/11/2008 8:25 AM Buy
None
47.20 60.00
as of 12/24/2008
1 Week down  -8.00 %
1 Month down  -9.64 %
3 Months down  -2.82 %
1 YTD down  -3.25 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy